|Articles|March 31, 2023

AJMC® in the Press, March 31, 2023

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

An article by mHealth Intelligence referenced a study published in the March 2023 issue of The American Journal of Managed Care^®. The study, “Provision of Telemental Health Before and After COVID-19 Onset,” examined prevalence of telemedicine services that were provided by mental health care organizations before and after the start of the COVID-19 pandemic in the United States.

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Trending on AJMC

AJMC® in the Press, March 31, 2023

Related Content

Smartwatch Study Links Midlife to Rising Nighttime Awakenings in Women

FDA Approves Gwyn Lo, a New Low-Dose Contraceptive Patch

Global HepB3 Coverage Reaches 81.8%, but Regional Gaps Persist

Rituximab Matches Ocrelizumab in Head-to-Head MS Trial

Gaps Persist in Interstitial Lung Disease Care

Trending on AJMC

FDA Approves Moderna’s mRNA Flu Vaccine After Phase 3 Success

5 Novel FDA Approvals That Signal a Shift Toward Convenience-Driven Care

GLP-1 Plus Glucagon: The Mechanistic Case for Dual Receptor Agonism in Obesity and MASH

Almost No Public Awareness of Lp(a), Elevated CVD Risk in the US: Katherine Wilemon

Rituximab Matches Ocrelizumab in Head-to-Head MS Trial

A Look at PBM Reform and Transparency: Payer, Provider and Patient Impact

AJMC® in the Press, March 31, 2023

Related Content

Smartwatch Study Links Midlife to Rising Nighttime Awakenings in Women

FDA Approves Gwyn Lo, a New Low-Dose Contraceptive Patch

Global HepB3 Coverage Reaches 81.8%, but Regional Gaps Persist

Rituximab Matches Ocrelizumab in Head-to-Head MS Trial

Gaps Persist in Interstitial Lung Disease Care

Trending on AJMC

FDA Approves Moderna’s mRNA Flu Vaccine After Phase 3 Success

5 Novel FDA Approvals That Signal a Shift Toward Convenience-Driven Care

GLP-1 Plus Glucagon: The Mechanistic Case for Dual Receptor Agonism in Obesity and MASH

Almost No Public Awareness of Lp(a), Elevated CVD Risk in the US: Katherine Wilemon

Rituximab Matches Ocrelizumab in Head-to-Head MS Trial